EcoDrugPlus

Cholinergic Receptor Muscarinic 3

Ensembl ID : ENSCCRG00000062872
Gene Symbol: CHRM3
1 Cross references
184 Possible Orthologues:

Cholinergic Receptor Muscarinic 3

Ensembl ID : ENSCCRG00000055880
Gene Symbol: CHRM3
1 Cross references
184 Possible Orthologues:

Cholinergic Receptor Muscarinic 4

Ensembl ID : ENSCCRG00000075300
Gene Symbol: CHRM4
1 Cross references
184 Possible Orthologues:

Cholinergic Receptor Muscarinic 5

Ensembl ID : ENSCCRG00000075415
Gene Symbol: CHRM5
1 Cross references
194 Possible Orthologues:

Cholinergic Receptor, Muscarinic 2a

Ensembl ID : ENSCCRG00000079628
Gene Symbol: CHRM2A
1 Cross references
194 Possible Orthologues:

Cholinergic Receptor, Muscarinic 2a

Ensembl ID : ENSCCRG00000060046
Gene Symbol: CHRM2A
1 Cross references
189 Possible Orthologues:

Cholinergic Receptor, Muscarinic 5b

Ensembl ID : ENSCCRG00000033453
Gene Symbol: CHRM5B
1 Cross references
187 Possible Orthologues:

Cholinergic Receptor, Muscarinic 5b

Ensembl ID : ENSCCRG00000014640
Gene Symbol: CHRM5B
1 Cross references
187 Possible Orthologues:

Cholinergic Receptor, Nicotinic, Alpha 4b

Ensembl ID : ENSCCRG00000016577
Gene Symbol: CHRNA4B
1 Cross references
191 Possible Orthologues:

Cholinergic Receptor, Nicotinic, Alpha 4b

Ensembl ID : ENSCCRG00000007242
Gene Symbol: CHRNA4B
1 Cross references
192 Possible Orthologues:

Cholinergic Receptor, Nicotinic, Alpha 7a (Neuronal)

Ensembl ID : ENSCCRG00000060541
Gene Symbol: CHRNA7A
1 Cross references
205 Possible Orthologues:

Cholinergic Receptor, Nicotinic, Alpha 7a (Neuronal)

Ensembl ID : ENSCCRG00000016316
Gene Symbol: CHRNA7A
1 Cross references
205 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).